Zevra Therapeutics (ZVRA) Other financing activities (2014 - 2022)

Zevra Therapeutics has reported Other financing activities for 7 years, with the latest figure at -$68000.0 in Q4 2022.

• For the quarter ending Q4 2022, Other financing activities rose 95.59% year-over-year to -$68000.0; the trailing twelve-month figure through Sep 2024 stood at -$68000.0 (changed 0.0% YoY), and the FY2024 full-year result was $2.1 million, changed N/A from the prior year.
• Other financing activities for Q4 2022 stood at -$68000.0, down from $68000.0 in the prior quarter.
• The five-year high for Other financing activities was $2.9 million in Q1 2021, with the low at -$1.5 million in Q4 2021.
• Historically, Other financing activities has averaged $196000.0 across 3 years, with a median of $34000.0 in 2020.
• Annual changes were most pronounced in 2021 — Other financing activities jumped 8373.53% — and 2022, when it sank 97.64%.
• Zevra Therapeutics' Other financing activities stood at -$63000.0 in 2020, then plunged by 2349.21% to -$1.5 million in 2021, then soared by 95.59% to -$68000.0 in 2022.
• The last three Other financing activities figures came in at -$68000.0 (Q4 2022), $68000.0 (Q1 2022), and -$1.5 million (Q4 2021), per Business Quant data.